Cellectar awarded $2 million grant to expand its ongoing phase 1 study of iopofosine i 131 in pediatric brain tumors

Florham park, n.j., sept. 22, 2022 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced it has been awarded $1.98 million in additional grant funding to expand its ongoing phase 1 study of iopofosine i 131 (iopofosine) in children and adolescents with inoperable relapsed or refractory high grade gliomas (hggs).
CLRB Ratings Summary
CLRB Quant Ranking